Skip to main
EXEL
EXEL logo

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 28 analyst ratings
Buy
Strong Buy 39%
Buy 25%
Hold 36%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. has demonstrated robust quarterly growth, with Cabometyx achieving a 20% year-over-year increase and projected revenues surpassing $2 billion by 2025, reflecting its strong performance in the renal cell carcinoma (RCC) market. The company is also likely to expand its revenue base with expected strong penetration among neuroendocrine tumor (NET) patients, highlighted by feedback from oncologists indicating Cabo's significant potential utility. Overall, Exelixis appears well-positioned for additional value creation through its existing portfolio and upcoming product opportunities, presenting a favorable outlook amidst current market conditions.

Bears say

The financial outlook for Exelixis Inc. is negatively impacted by a potential decline in market share for cabozantinib across various indications, with expected peak market shares dropping to 20% in the first-line RCC setting, 40% in the second-line RCC setting, and 10% in HCC following regulatory failures. Additionally, the company faces significant risks including potential setbacks in research and development, increased competition, lower-than-expected product sales, and the risk of generic erosion impacting the cabozantinib franchise. Concerns have also been raised regarding the tolerability profile of cabozantinib, which may deter physicians from prescribing the drug, further complicating future revenue generation.

Exelixis (EXEL) has been analyzed by 28 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 25% recommend Buy, 36% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 28 analysts, Exelixis (EXEL) has a Buy consensus rating as of Jul 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.